Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis
This observational, longitudinal retrospective, noncomparative study was designed to assess the persistence and effectiveness of golimumab as a second anti-tumor necrosis factor (TNF) drug in patients with spondyloarthritis requiring discontinuation from a first anti-TNF drug.Data were collected ret...
| Autores: | , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2021 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:272006 |
| Acceso en línea: | https://ddd.uab.cat/record/272006 https://dx.doi.org/urn:doi:10.1097/MD.0000000000025223 |
| Access Level: | acceso abierto |
| Palabra clave: | Ankylosing spondylitis Anti- tumor necrosis factor Golimumab Psoriatic arthritis Spondyloarthritis Tumor necrosis factor inhibitor |
| id |
ES_d16129d8ca4479110a018adb0def49b4 |
|---|---|
| oai_identifier_str |
oai:ddd.uab.cat:272006 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritisA retrospective studyAlegre-Sancho, Juan José|||0000-0003-1641-0875Juanola, Xavier|||0000-0001-5998-6300Rodriguez-Heredia, José Manuel|||0000-0002-4493-1419Manero, JavierVilla-Blanco, IgnacioLaiz, Ana|||0000-0002-2820-4801Arteaga, María J.Cea-Calvo, LuisGonzález, Carlos M.|||0000-0001-5511-8274Ankylosing spondylitisAnti- tumor necrosis factorGolimumabPsoriatic arthritisSpondyloarthritisTumor necrosis factor inhibitorThis observational, longitudinal retrospective, noncomparative study was designed to assess the persistence and effectiveness of golimumab as a second anti-tumor necrosis factor (TNF) drug in patients with spondyloarthritis requiring discontinuation from a first anti-TNF drug.Data were collected retrospectively for all patients with axial spondyloarthritis or psoriatic arthritis from 20 rheumatology clinics in Spain who started golimumab as a second anti-TNF drug between January 2013 and December 2015. Golimumab persistence was assessed with Kaplan-Meier survival analysis, and associated factors were assessed with Cox regression analysis.210 patients started golimumab as a second anti-TNF drug: 131 with axial spondyloarthritis and 79 with psoriatic arthritis. In axial spondyloarthritis patients, the mean (standard deviation) Bath Ankylosing Spondylitis Disease Activity Index score at baseline was 5.5 (2.1), decreasing to 3.9 (2.0) at month 3 and 3.5 (2.0) at year 1, and remaining stable thereafter. In psoriatic arthritis patients, mean (standard deviation) baseline Disease Activity Score was 4.0 (1.3), reducing to 2.5 (1.2) at month 3 and to 2.2 (1.3) at year 1. Corresponding improvements were recorded from baseline in C-reactive protein levels and erythrocyte sedimentation rates. The probability of persistence of treatment with golimumab was 80% at year 1, 70% at year 2 and 65% at years 3 and year 4, and was similar in those who had stopped the first anti-TNF due to loss of efficacy or other reasons. Cox regression analysis showed that the probability of survival with golimumab was higher in patients with higher erythrocyte sedimentation rate, in patients with axial spondyloarthritis than with psoriatic arthritis, and in those who had discontinued adalimumab as first anti-TNF. Seventy-two patients (34.3%) discontinued golimumab during follow-up, 50 of them due to lack of efficacy.In patients with spondyloarthritis requiring discontinuation from a first anti-TNF drug, treatment with golimumab was effective and showed a high probability of persistence up to 4years of treatment. 22021-01-0120212021-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/272006https://dx.doi.org/urn:doi:10.1097/MD.0000000000025223reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2720062026-06-06T12:50:31Z |
| dc.title.none.fl_str_mv |
Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis A retrospective study |
| title |
Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis |
| spellingShingle |
Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis Alegre-Sancho, Juan José|||0000-0003-1641-0875 Ankylosing spondylitis Anti- tumor necrosis factor Golimumab Psoriatic arthritis Spondyloarthritis Tumor necrosis factor inhibitor |
| title_short |
Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis |
| title_full |
Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis |
| title_fullStr |
Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis |
| title_full_unstemmed |
Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis |
| title_sort |
Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis |
| dc.creator.none.fl_str_mv |
Alegre-Sancho, Juan José|||0000-0003-1641-0875 Juanola, Xavier|||0000-0001-5998-6300 Rodriguez-Heredia, José Manuel|||0000-0002-4493-1419 Manero, Javier Villa-Blanco, Ignacio Laiz, Ana|||0000-0002-2820-4801 Arteaga, María J. Cea-Calvo, Luis González, Carlos M.|||0000-0001-5511-8274 |
| author |
Alegre-Sancho, Juan José|||0000-0003-1641-0875 |
| author_facet |
Alegre-Sancho, Juan José|||0000-0003-1641-0875 Juanola, Xavier|||0000-0001-5998-6300 Rodriguez-Heredia, José Manuel|||0000-0002-4493-1419 Manero, Javier Villa-Blanco, Ignacio Laiz, Ana|||0000-0002-2820-4801 Arteaga, María J. Cea-Calvo, Luis González, Carlos M.|||0000-0001-5511-8274 |
| author_role |
author |
| author2 |
Juanola, Xavier|||0000-0001-5998-6300 Rodriguez-Heredia, José Manuel|||0000-0002-4493-1419 Manero, Javier Villa-Blanco, Ignacio Laiz, Ana|||0000-0002-2820-4801 Arteaga, María J. Cea-Calvo, Luis González, Carlos M.|||0000-0001-5511-8274 |
| author2_role |
author author author author author author author author |
| dc.subject.none.fl_str_mv |
Ankylosing spondylitis Anti- tumor necrosis factor Golimumab Psoriatic arthritis Spondyloarthritis Tumor necrosis factor inhibitor |
| topic |
Ankylosing spondylitis Anti- tumor necrosis factor Golimumab Psoriatic arthritis Spondyloarthritis Tumor necrosis factor inhibitor |
| description |
This observational, longitudinal retrospective, noncomparative study was designed to assess the persistence and effectiveness of golimumab as a second anti-tumor necrosis factor (TNF) drug in patients with spondyloarthritis requiring discontinuation from a first anti-TNF drug.Data were collected retrospectively for all patients with axial spondyloarthritis or psoriatic arthritis from 20 rheumatology clinics in Spain who started golimumab as a second anti-TNF drug between January 2013 and December 2015. Golimumab persistence was assessed with Kaplan-Meier survival analysis, and associated factors were assessed with Cox regression analysis.210 patients started golimumab as a second anti-TNF drug: 131 with axial spondyloarthritis and 79 with psoriatic arthritis. In axial spondyloarthritis patients, the mean (standard deviation) Bath Ankylosing Spondylitis Disease Activity Index score at baseline was 5.5 (2.1), decreasing to 3.9 (2.0) at month 3 and 3.5 (2.0) at year 1, and remaining stable thereafter. In psoriatic arthritis patients, mean (standard deviation) baseline Disease Activity Score was 4.0 (1.3), reducing to 2.5 (1.2) at month 3 and to 2.2 (1.3) at year 1. Corresponding improvements were recorded from baseline in C-reactive protein levels and erythrocyte sedimentation rates. The probability of persistence of treatment with golimumab was 80% at year 1, 70% at year 2 and 65% at years 3 and year 4, and was similar in those who had stopped the first anti-TNF due to loss of efficacy or other reasons. Cox regression analysis showed that the probability of survival with golimumab was higher in patients with higher erythrocyte sedimentation rate, in patients with axial spondyloarthritis than with psoriatic arthritis, and in those who had discontinued adalimumab as first anti-TNF. Seventy-two patients (34.3%) discontinued golimumab during follow-up, 50 of them due to lack of efficacy.In patients with spondyloarthritis requiring discontinuation from a first anti-TNF drug, treatment with golimumab was effective and showed a high probability of persistence up to 4years of treatment. |
| publishDate |
2021 |
| dc.date.none.fl_str_mv |
2 2021-01-01 2021 2021-01-01 |
| dc.type.none.fl_str_mv |
Article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://ddd.uab.cat/record/272006 https://dx.doi.org/urn:doi:10.1097/MD.0000000000025223 |
| url |
https://ddd.uab.cat/record/272006 https://dx.doi.org/urn:doi:10.1097/MD.0000000000025223 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc/4.0/ |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.source.none.fl_str_mv |
reponame:Dipòsit Digital de Documents de la UAB instname:Universitat Autònoma de Barcelona |
| instname_str |
Universitat Autònoma de Barcelona |
| reponame_str |
Dipòsit Digital de Documents de la UAB |
| collection |
Dipòsit Digital de Documents de la UAB |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869420257200832512 |
| score |
15,300719 |